|تعداد مشاهده مقاله||12,794,473|
|تعداد دریافت فایل اصل مقاله||6,126,689|
Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
|Middle East Journal of Cancer|
|مقاله 11، دوره 14، شماره 4 - شماره پیاپی 56، دی 2023، صفحه 570-577 اصل مقاله (1.27 M)|
|نوع مقاله: Original Article(s)|
|شناسه دیجیتال (DOI): 10.30476/mejc.2023.95281.1763|
|Mahsa Sepahvand1؛ Alireza Salehi* 1؛ Ali Omidvari1؛ Shapour Omidvari2؛ Mohammad Mohammadianpanah3|
|1MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran|
|2Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran|
|3Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran|
|Background: Prostate cancer remains one of the most common and lethal cancers among men worldwide. This study aimed to investigate the characteristics, prognostic factors, and outcomes of patients with prostate cancer who were treated and followed up in Shiraz, southern Iran over the past 12 years.|
Method: This retrospective medical chart review was performed on 872 patients with prostate cancer who were treated and followed up in the Radiation Oncology Department of Shiraz University of Medical Sciences. The survival analysis was conducted for the patients, and the receiver operating characteristic (ROC) curve analysis was performed for the prostate-specific antigen (PSA) level.
Results: The median age of the patients at presentation was 69 years (range 35-91 years). In terms of local treatments, 28% of the patients underwent prostatectomy, and 23% were treated with transurethral resection of the prostate. The remaining 49% of patients were treated with non-surgical therapies. Patients between 55 and 75 years had the longest survival duration. The shortest survival was observed in the third Gleason group and those over 75 years old, while the first Gleason group and patients younger than 55 years had the longest survival duration. Hypoalbuminemia had no effect on the survival duration. A PSA level of 33.8 ng/dl was the most suitable cutoff point to predict bone metastasis, and patients with a PSA level of more than 33.8 ng/dl had significantly less survival duration than the others.
Conclusion: More aggressive treatment and shorter follow-up intervals are recommended for patients with an initial PSA level of more than 33.8 and those younger than 55 years old.
تازه های تحقیق
Alireza Salehi (Google Scholar)
|Prostatic neoplasms؛ Survival analysis؛ Prostate-specific antigen؛ Prognosis؛ ROC curve|
تعداد مشاهده مقاله: 2,946
تعداد دریافت فایل اصل مقاله: 253